Trump’s Malaria Drug Fails Another Trial On Covid-19 Patients

'Dotun Akintomide
Writer

Ad

Venezuelan Democracy Activist María Corina Machado Wins Nobel Peace Prize, Trump Snubbed

By Obinna Uballa Venezuelan opposition leader and democracy campaigner, María Corina Machado, has been awarded the 2025 Nobel Peace Prize for her “tireless work promoting democratic rights for the people of Venezuela” and her “struggle to achieve a just and peaceful transition from dictatorship to democracy.” Machado, who has been in hiding since August 2024…

UNILAG, UI Top 2026 Times World University Rankings in Nigeria

By Obinna Uballa The University of Lagos (UNILAG) has emerged as the highest-ranked university in Nigeria, alongside the University of Ibadan (UI), in the 2026 Times Higher Education (THE) World University Rankings released on Thursday, October 9, 2025. According to the global ranking, UNILAG and UI both placed in the 801-1000 band out of more…

Oil Prices Set for Moderate Dip on Gaza Ceasefire

Crude oil prices are on course for another weekly decline following the news of a ceasefire between the Israeli government and Hamas, which was ratified today by Tel Aviv. At the time of writing, Brent crude was trading at $64.90 per barrel, with West Texas Intermediate at $61.28, as the Middle East war premium vanished. “This (deal) saw the…

Ad

U.S. President Donald Trump’s malaria drug which he touted as a “game changer” for coronavirus has again failed to show a benefit in hospitalised patients.

A study published in the New England Journal of Medicine reported that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death.

“We didn’t see any association between getting this medicine and the chance of dying or being intubated,” lead researcher Dr. Neil Schluger told Reuters in a telephone interview.

“The patients who got the drug didn’t seem to do any better.”

Among patients given hydroxychloroquine, 32.3% ended up needing a ventilator or dying, compared with 14.9% of patients who were not given the drug.

But doctors were more likely to give hydroxychloroquine to sicker patients, so researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center adjusted the rates to account for that.

They concluded that the drug may not have hurt patients, but it clearly did not help.

Decades old hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, also showed no benefit when combined with the antibiotic azithromycin, Schluger’s team reported.

Azithromycin alone also showed no benefit.

Last month, doctors at the U.S. Department of Veterans Affairs reported that hydroxychloroquine did not help COVID-19 patients and might pose a higher risk of death.

That analysis of medical records showed a death rate of 28% when the drug was given in addition to standard treatments, compared to 11% with standard care alone.

In the latest study, 811 patients got hydroxychloroquine and 565 did not.

Because they were not randomly assigned to receive hydroxychloroquine or a placebo, “the study should not be taken to rule out either benefit or harm” for the drug, researchers said.

Randomized trials, the gold standard for tests of new therapies, should continue, they added.

But for now, “the guidance in our hospital has changed so we don’t recommend giving hydroxychloroquine to hospitalised patients,” said Dr. Schluger, chief of the division of pulmonary, allergy and critical care medicine at Irving.

Reuters/NAN

Ad

Unlocking Opportunities in the Gulf of Guinea during UNGA80
X whatsapp